CAM Capital
CAM Capital engages in both trading activities and fundamentally driven investments.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed CAM Capital Information
Geographic Data
Address: 1330 Sixth Avenue Floor 20
City: New York
State: NY
Zip: 10019
Country: US
Financial Info
Stage:
Raised Last:
$2M
Raised Total:$2M
Social
Facebook
Crunchbase
Metrics
5,324,292Website Global Rank
1,727Website Monthly Traffic
Twitter Followers
Description
CAM Capital manages private family investments. The firm’s goal is to achieve long-term compounded growth of its portfolio using a diversified, opportunistic investment strategy. In pursuit of this goal, CAM Capital engages in both trading activities and fundamentally driven investments. Our investments span all parts of the corporate capital structure in both the private and public markets. ###Caxton Alternative Management announced that it is changing its name to CAM Capital.###
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 9/2020 | ESCAPE Bio | Venture Round | 73M |
| 5/2022 | Kriya Therapeutics | Series C | 0 |
| 7/2021 | Kriya Therapeutics | Series B | 0 |
| 9/2017 | GTx | Post-IPO Equity | 48.5M |
| 8/2017 | Molecular Templates | Post-IPO Equity | 60M |
| 9/2013 | Infinity SDC | Venture Round | 77.1M |
| 5/2018 | MEI Pharma | Post-IPO Equity | 75M |
| 4/2021 | Antios Therapeutics | Series B | 0 |
| 2/2015 | Agile Therapeutics | Post-IPO Equity | 0 |
| 11/2021 | Antios Therapeutics | Series B | 0 |
| 6/2020 | Cardiff Oncology | Post-IPO Equity | 13.5M |
| 4/2019 | Satsuma Pharmaceuticals | Series B | 0 |
| 11/2018 | Antios Therapeutics | Series A | 0 |
| 3/2020 | Primmune Therapeutics | Seed Round | 0 |
| 10/2020 | Primmune Therapeutics | Series A | 0 |
| 1/2022 | Kyverna Therapeutics | Series B | 0 |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 4/2016 | Kala Pharmaceuticals | Series C | 68M |
| 9/2021 | LEXEO Therapeutics | Series B | 0 |
| 4/2021 | AltruBio | Series A | 63M |
| 4/2021 | Arcellx | Series C | - |
| 1/2022 | AvengeBio | Series A | 0 |
| 8/2020 | ESSA Pharma | Post-IPO Equity | 0 |
| 5/2020 | Palvella Therapeutics | Series C | 0 |
| 10/2020 | Rezolute | Post-IPO Equity | 41M |
| 5/2022 | Kriya Therapeutics | Series C | 0 |
| 1/2022 | Kyverna Therapeutics | Series B | 0 |
| 1/2022 | AvengeBio | Series A | 0 |
| 11/2021 | Antios Therapeutics | Series B | 0 |
| 9/2021 | LEXEO Therapeutics | Series B | 0 |
| 7/2021 | Kriya Therapeutics | Series B | 0 |
| 4/2021 | AltruBio | Series A | 0 |
| 4/2021 | Arcellx | Series C | - |
| 4/2021 | Antios Therapeutics | Series B | 0 |
| 10/2020 | Primmune Therapeutics | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
